TRIM29 and breast carcinoma: Evaluation of TRIM29 expression pattern among all TNBC patients using RNA-seq data from the TCGA database showed that most TNBC tumors, whether classified via PAM50 (Prediction Analysis of Microarray 50) status (Fig. 1E) or classified based on IHC (immunohistochemistry) status (Fig. 1F), had an elevated expression level of TRIM29 compared to other subtypes of breast cancer.